• Molecular Partners posted a net loss attributable to shareholders of CHF 13.14 million, narrowing from CHF 16.77 million a year earlier; loss per share improved to CHF 0.35 from CHF 0.45.
• Operating loss narrowed to CHF 13.44 million as total operating expenses fell to CHF 13.44 million from CHF 16.14 million.
• Research and development expenses declined to CHF 9.45 million from CHF 11.92 million, including CHF 349,000 of expense reimbursement from Orano Med tied to the Radio Darpin Therapies cost-sharing agreement.
• Net cash used in operating activities improved to CHF 14.24 million from CHF 17.08 million, while cash and cash equivalents fell to CHF 64.25 million from CHF 82.65 million at Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.